Alterity Therapeutics (ATHE) Current Deferred Revenue (2014 - 2015)
Alterity Therapeutics' (ATHE) quarterly Current Deferred Revenue came in at $55652.2 in Q4 2015, down 29.73% year-on-year from $79194.8 in Q4 2014, and down 29.73% quarter-over-quarter from $79194.8 in Q4 2014.
Alterity Therapeutics (ATHE) Current Deferred Revenue (2014 - 2015) Analysis & Trends
Alterity Therapeutics' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $55652.2 for Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alterity Therapeutics | 29.68 Bn | 29.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 55,652.20 |
| Dec 31, 2014 | 79,194.76 |